Test Price
2,800 AED✅ Home Collection Available
AGPAT2 Gene Lipodystrophy Generalized Type 1 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Clinical Precision: 99.9% diagnostic sensitivity via ISO 9001:2015 certified processing.
- Premium Logistics: VIP mobile phlebotomy with ISO‑certified cold‑chain home collection (daily 8 AM – 11 PM).
- Clinical Guidance: Post‑test telephone consultation by specialist physicians for result interpretation.
- Insurance Verification: Direct coverage check via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next‑Generation Sequencing (NGS) test analyzes the entire coding region and flanking intronic boundaries of the AGPAT2 gene to detect mutations causing congenital generalized lipodystrophy type 1 (CGL1), a rare autosomal recessive metabolic disorder. The test provides definitive molecular diagnosis and informs long‑term management and family planning.
| Feature | Our Test (NGS – AGPAT2 Full Gene) | Closest Alternative (Sanger Sequencing or Panel) |
|---|---|---|
| Methodology | NGS (Next‑Generation Sequencing) | Sanger Sequencing (single exon) or targeted panel |
| Gene Coverage | 100% coding + flanking intronic regions | Limited to selected exons |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Report Depth | Clinically actionable ACMG variant classification | Basic variant presence/absence |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics, I emphasize that while this NGS test provides definitive molecular diagnosis for congenital generalized lipodystrophy type 1, clinical correlation with physical findings and metabolic parameters remains essential. Never discontinue prescribed medications without physician guidance. This test helps confirm or exclude CGL1, guiding management and family planning decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not stop prescribed medications without consulting your doctor. Genetic test results inform long‑term management; they do not replace current treatment.
Exclusion Criteria & Red Flags
- Unwilling or unable to undergo pre‑test genetic counselling as per DHA requirements.
- Severe hemophilia or bleeding disorders without prior medical clearance.
- Active skin infection or open wound at the venipuncture site.
- Seek urgent medical attention if you develop fever >38.5°C, unusual bruising, or signs of site infection (redness, pus, swelling) post‑collection.
Patient FAQ & Clinical Guidance
1. What does the AGPAT2 gene test diagnose?
This NGS detects mutations in the AGPAT2 gene responsible for congenital generalized lipodystrophy type 1 (CGL1), a rare autosomal recessive condition characterized by near‑total loss of subcutaneous fat and metabolic abnormalities.
2. How long until I receive my results?
Results are delivered within 3 to 4 weeks from sample receipt, ensuring thorough NGS analysis and expert clinical interpretation.
3. Is home blood collection available in the UAE?
Yes, we offer ISO‑certified cold‑chain home collection from 8 AM to 11 PM across all UAE emirates, performed by a DHA‑licensed phlebotomist. Sample type: 2–5 mL whole blood in EDTA tube.
4. Do I need pre‑test genetic counselling?
Yes, a mandatory pre‑test counselling session is required to draw a pedigree chart of affected family members and discuss implications before sample collection.
UAE Regulatory & Data Privacy Adherence
All procedures at DNA Labs UAE strictly comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. The laboratory is ISO 9001:2015 certified and holds DHA facility license 1143.
Clinical & Logistical Metadata
| Test Name | AGPAT2 Gene Sequencing (Congenital Generalized Lipodystrophy Type 1) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (2–5 mL in EDTA tube) |
| Methodology Used | Next‑Generation Sequencing (NGS) of full coding and flanking intronic regions |
| ICD‑10‑CM Code | E88.1 (Lipodystrophy, not elsewhere classified) |
| LOINC Code | 82321-5 (AGPAT2 gene mutation analysis in Blood or Tissue by NGS) |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians